Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P53675 (
CHC22
)
19
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Congenital inability to feel pain is very rare but the identification of causative genes has yielded significant insights into pain pathways and also novel targets for pain treatment. We report a novel recessive disorder characterized by congenital insensitivity to pain, inability to feel touch, and cognitive delay. Affected individuals harboured a homozygous missense mutation in
CLTCL1
encoding the
CHC22
clathrin heavy chain, p.E330K, which we demonstrate to have a functional effect on the protein. We found that
CLTCL1
is significantly upregulated in the developing human brain, displaying an expression pattern suggestive of an early neurodevelopmental role. Guided by the disease phenotype, we investigated the role of
CHC22
in two human neural crest differentiation systems; human induced pluripotent stem cell-derived nociceptors and TRKB-dependant SH-SY5Y cells. In both there was a significant downregulation of
CHC22
upon the onset of neural differentiation. Furthermore, knockdown of
CHC22
induced neurite outgrowth in neural precursor cells, which was rescued by stable overexpression of small interfering RNA-resistant
CHC22
, but not by mutant
CHC22
. Similarly, overexpression of wild-type, but not mutant,
CHC22
blocked neurite outgrowth in cells treated with retinoic acid. These results reveal an essential and non-redundant role for
CHC22
in neural crest development and in the genesis of pain and touch sensing neurons.
...
PMID:A novel disorder reveals clathrin heavy chain-22 is essential for human pain and touch development. 2606 9
CHC22
clathrin plays a key role in intracellular membrane traffic of the insulin-responsive glucose transporter GLUT4 in humans. We performed population genetic and phylogenetic analyses of the
CHC22
-encoding
CLTCL1
gene, revealing independent gene loss in at least two vertebrate lineages, after arising from gene duplication. All vertebrates retained the paralogous
CLTC
gene encoding CHC17 clathrin, which mediates endocytosis. For vertebrates retaining
CLTCL1
, strong evidence for purifying selection supports
CHC22
functionality. All human populations maintained two high frequency
CLTCL1
allelic variants, encoding either methionine or valine at position 1316. Functional studies indicated that
CHC22
-V1316, which is more frequent in farming populations than in hunter-gatherers, has different cellular dynamics than M1316-
CHC22
and is less effective at controlling GLUT4 membrane traffic, altering its insulin-regulated response. These analyses suggest that ancestral human dietary change influenced selection of allotypes that affect
CHC22
's role in metabolism and have potential to differentially influence the human insulin response.
...
PMID:Genetic diversity of CHC22 clathrin impacts its function in glucose metabolism. 3115 24